EPO upholds Bayer's Xarelto dosage patents

04-11-2021

Alex Baldwin

EPO upholds Bayer's Xarelto dosage patents

nitpicker / Shutterstock.com

Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office (EPO), the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto (rivaroxaban).


EPO, Appeal, Bayer Pharmaceuticals, Generics, Xarelto, Rivaroxaban, Cohausz & Florack

LSIPR